Clinical Trial

Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem cells derived from their individual tumors, alongside standard of care radiation and TMZ.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-05-17; most recent amendment 2025-05-13.
Status change: Not Yet Recruiting → Recruiting 2024-04-08
Trial Details
NCT Number NCT05380349
Lead Sponsor Swedish Medical Center
Conditions Newly Diagnosed Glioblastoma
Enrollment 10 participants
Start Date 2024-04-19
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-16